American Society of Hematology

Figure 1

$Figure 1. Serum IgG, IgA, and IgM levels on ibrutinib compared with pretreatment baseline. Scatter plot of change in (A) IgG (n = 35 at 6 and 12 months; n = 21 at 24 months), (B) IgA (n = 43 at 6 and 12 months; n = 28 at 24 months), and (C) IgM (n = 34 at 6 and 12 months; n = 23 at 24 months), in treatment-naive (○) and relapsed or refractory (♦) patients. Only paired data are shown. Horizontal lines denote median values. Titers of polyreactive (D) IgG, (E) IgA, and (F) IgM (mean ± SEM) prior to treatment (PRE), and at 6 and 12 months (n = 21). Statistical significance is indicated by *P < .05, **P < .01, ***P < .001, or ****P < .0001.$

Serum IgG, IgA, and IgM levels on ibrutinib compared with pretreatment baseline. Scatter plot of change in (A) IgG (n = 35 at 6 and 12 months; n = 21 at 24 months), (B) IgA (n = 43 at 6 and 12 months; n = 28 at 24 months), and (C) IgM (n = 34 at 6 and 12 months; n = 23 at 24 months), in treatment-naive (○) and relapsed or refractory (♦) patients. Only paired data are shown. Horizontal lines denote median values. Titers of polyreactive (D) IgG, (E) IgA, and (F) IgM (mean ± SEM) prior to treatment (PRE), and at 6 and 12 months (n = 21). Statistical significance is indicated by *P < .05, **P < .01, ***P < .001, or ****P < .0001.

This Feature Is Available To Subscribers Only